Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARISOPRODOL COMPOUND vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Relief of discomfort associated with acute, painful musculoskeletal conditions,As an adjunct to rest, physical therapy, and other measures
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Carisoprodol is metabolized by CYP2C19 to meprobamate (active metabolite). Aspirin is hydrolyzed by esterases in the liver and plasma to salicylic acid, which is further conjugated. Codeine is metabolized by CYP2D6 to morphine (active) and by CYP3A4 to norcodeine.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Carisoprodol is approximately 60% bound to plasma proteins, mainly albumin.
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Volume of distribution is approximately 0.6–0.8 L/kg, indicating distribution into total body water.
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral bioavailability is nearly complete (close to 100%) due to rapid and extensive absorption.
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild-moderate impairment; use caution.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment, reduce dose or increase interval; specific guidelines not established.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Not recommended for pediatric patients due to aspirin content and risk of Reye syndrome.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Initiate at lowest effective dose; monitor for CNS depression, falls, and aspirin-related bleeding. Avoid in patients ≥65 years due to risks of dizziness, sedation, and GI bleeding.
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
None
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Risk of dependence, abuse, and withdrawal with carisoprodol and codeine,CYP2D6 ultrarapid metabolizers may have morphine toxicity from codeine,Reye's syndrome risk in children with viral illness (aspirin),GI bleeding risk with aspirin,Respiratory depression with codeine,Sedation and impaired motor function,Hepatic impairment,Renal impairment
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Hypersensitivity to carisoprodol, meprobamate, aspirin, codeine, or any component,Porphyria,Acute intermittent porphyria,Children with viral illness (aspirin) due to Reye's syndrome risk,Breastfeeding (codeine),Severe renal or hepatic impairment,GI bleeding or peptic ulcer disease (aspirin),Concurrent use of MAOIs or within 14 days,Respiratory depression (codeine)
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
Avoid alcohol and grapefruit juice. Alcohol increases CNS depression and risk of hepatotoxicity. Grapefruit juice may inhibit metabolism, leading to increased levels and toxicity.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fetal harm if used during the first trimester due to possible neural tube defects based on limited reports. In the second and third trimesters, maternal use may cause neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and respiratory depression if used near term. Carisoprodol is not recommended during pregnancy unless benefit outweighs risk.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Carisoprodol is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2-4 based on small studies. An infant would receive a weight-adjusted dose of about 4-8% of the maternal dose, which may cause sedation, drowsiness, or irritability in the neonate. Breastfeeding is not recommended during carisoprodol use, especially in premature infants or those with hepatic impairment. If used, monitor infant for signs of CNS depression.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
No specific dosing adjustments for carisoprodol are established in pregnancy. However, due to increased plasma volume and altered hepatic metabolism in pregnancy, the drug's half-life may be reduced. Clinical monitoring for efficacy and maternal side effects (e.g., drowsiness, dizziness) is recommended. Use the lowest effective dose for the shortest duration. Consider avoidance of the compound formulation with aspirin or other NSAIDs, which have additional risks.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Carisoprodol is metabolized to meprobamate, a controlled substance with abuse potential; use cautiously in patients with history of substance abuse. Combination with other CNS depressants (e.g., alcohol, benzodiazepines) increases sedation risk. Limit use to 2-3 weeks due to lack of efficacy beyond that and risk of dependence. Avoid in patients with porphyria because carisoprodol may be porphyrinogenic.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or frequency. This drug has abuse potential.,Inform your doctor if you have a history of drug or alcohol abuse, seizures, or liver/kidney disease.,Do not use for longer than 2-3 weeks unless directed by your doctor.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARISOPRODOL COMPOUND vs ESTROSTEP 21, answered by our medical review team.
CARISOPRODOL COMPOUND is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARISOPRODOL COMPOUND and ESTROSTEP 21 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARISOPRODOL COMPOUND is: 1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARISOPRODOL COMPOUND and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARISOPRODOL COMPOUND is classified as Category A/B. Carisoprodol is a pregnancy category C drug. Data from animal studies are insufficient or show adverse effects, but no adequate human studies exist. There is a potential risk of fe. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.